Calamos Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Calamos Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,390	Closed	-$3.52M	–	997
2026 Q1	$3.52M	Sell	15,390 -910	-6%	-$204K	0.01%	604
2025 Q4	$3.48M	Buy	16,300 +9,850	+153%	+$2.03M	0.01%	570
2025 Q3	$1.28M	Buy	+6,450	New	+$1.2M	﹤0.01%	675

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Calamos Advisors's ASND Position: Q2 2026 in Review

Calamos Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 15,390 shares — an estimated $3.52M sold.

Calamos Advisors first reported a position in ASND in Q3 2025 and held it in 3 quarters. The position peaked at $3.52M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Calamos Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Calamos Advisors sold 15,390 Ascendis Pharma A/S shares in Q2 2026, an estimated $3.52M.
Calamos Advisors first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 3 quarters.
Calamos Advisors's Ascendis Pharma A/S position peaked at $3.52M in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.